FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC
The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.
Related Articles
Social Determinants of Health Correlate With Receipt of Allo-HSCT in AML
Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.
Registration
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…
Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL
Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children’s Oncology Group trial AALL15P1
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of failure to achieve remission, relapse, and…
Pesticide exposure and increased risk of breast cancer for women in rural Brazil
Human exposure to pesticides has been linked to an increased incidence of various cancers. For breast cancer, previous studies have reported an increased risk of…
Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met
Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.
Epcoritamab Monotherapy Induces Complete Responses in R/R CLL
Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.